Technology ID
TAB-2717
Recombinant Stabilized Prefusion Protein of Respiratory Syncytial Virus for Use as a Subunit Vaccine
E-Numbers
E-081-2013-5
E-081-2013-4
E-081-2013-0
E-081-2013-1
E-081-2013-2
E-081-2013-3
Lead Inventor
McLellan, Jason (NIAID)
Co-Inventors
Gorman, Jason (NIAID)
Ofek, Gilad (NIAID)
Pancera, Marie (NIAID)
Sastry, Mallika (NIAID)
Srivatsan, Sanjay (NIAID)
Yang, Yongping (NIAID)
Chen, Lei (NIAID)
Soto, Cinque (NIAID)
Zhou, Tongqing (NIAID)
Graham, Barney (NIAID)
Kwong, Peter (NIAID)
Kanekiyo, Masaru (NIAID)
Joyce, Michael (NIAID)
Zhang, Baoshan (NIAID)
Stewart-Jones, Guillaume (NIAID)
Boyington, Jeffrey (NIAID)
Chen, Man (NIAID)
Chuang, Gwo-Yu (NIAID)
Georgiev, Ivelin (NIAID)
Applications
Vaccines
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Development Status
- Pre-clinical In vivo data available (animal)
Lead IC
NIAID
ICs
NIAID
The invention, a stabilized recombinant prefusion F protein (pre F), is a candidate subunit vaccine for Respiratory Syncytial Virus (RSV). Pre-F is stabilized in the prefusion conformation and displays epitopes not present in postfusion F protein. Several potent RSV neutralizing antibodies bind pre F, but not postfusion F. Therefore, immunization with pre F may elicit an immune response superior to the response generated by postfusion F.
NIH researchers have engineered pre F to expose an antigenic site 0, which is targeted by extremely potent RSV neutralizing antibodies. Structure-based design yielded several stabilized variants of pre F that maintained exposure of antigenic site 0 when subjected to extremes of pH, osmolality and temperature.
Preclinical in vivo data on stabilized pre F is available. Immunization of mice and macaques with antigenic site 0 stabilized pre F variants elicited high levels of RSV specific neutralizing activity.
NIH researchers have engineered pre F to expose an antigenic site 0, which is targeted by extremely potent RSV neutralizing antibodies. Structure-based design yielded several stabilized variants of pre F that maintained exposure of antigenic site 0 when subjected to extremes of pH, osmolality and temperature.
Preclinical in vivo data on stabilized pre F is available. Immunization of mice and macaques with antigenic site 0 stabilized pre F variants elicited high levels of RSV specific neutralizing activity.
Commercial Applications
- Vaccine for Respiratory Syncytial Virus
Competitive Advantages
- Vaccine stably exposes antigenic site in RSV F that permits generation of potent RSV neutralizing antibodies.
- There is currently no RSV vaccine on the market.
Licensing Contact: